Should you buy Novartis stock now?
Yes, the technical signal for Novartis is currently BUY. Novartis trades at $153.93 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.664 with falling momentum (signal: 0.916); RSI is at 50.0 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $155.37 points to 0.9% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Novartis stock?
The average analyst price target for Novartis is $155.37. The current price is $153.93, which gives an upside of 0.9%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $139.83 and $170.91.
Is Novartis a dividend stock?
Yes, Novartis is a dividend stock with a dividend yield of 3.04%. The latest dividend was $4.77 per share. The latest ex-dividend date (traded without the dividend) was 3/11/2026. The payout ratio is 57.2%, which is considered moderate. The next dividend payment is scheduled for 3/16/2026.
When does Novartis pay a dividend in 2026?
Novartis pays its next dividend on 3/16/2026. The latest dividend was $4.77 per share with an ex-dividend date of 3/11/2026. The dividend yield is 3.04%. The payout ratio of 57.2% points to moderate dividend coverage.
What is the risk of Novartis stock?
Novartis is rated as a stock with low risk. the annual standard deviation is 21.2%, which classifies the stock as low risk.
Is Novartis overvalued?
Novartis is considered fairly valued – the price is close to the analyst price target. Novartis has the following valuation ratios: a P/E ratio of 23.2 (moderately to highly valued), a P/S ratio of 5.1, a P/B ratio of 7.1. The stock trades close to the analyst price target and is considered fairly valued.
Is Novartis overbought?
No, Novartis is not overbought. RSI is at 50.0 (neutral zone). The technical indicators show: RSI is at 50.0 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.3% below the 20-day average (short-term downtrend). In addition, MACD is positive, but momentum is falling.
When is the next Novartis earnings report?
Novartis reports its next earnings on October 27, 2026. The stock currently trades at $153.93. With a P/E ratio of 23.2, the market will be watching closely whether earnings meet expectations.
Is Novartis shorted?
Novartis has minimal short interest of 0.30% of the free float, which is insignificant and points to very limited bearish sentiment.
Are insiders buying Novartis stock?
Yes, insiders are net buyers of Novartis – they are buying more shares than they are selling. Across the last 20 reported transactions, the split is 3 purchases and 17 sales, with a net 56,881,104 $ bought. Active buyers include Novartis Bioventures Ltd. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Novartis a good stock?
Based on our total score, Novartis is rated as a good stock with a total score of 64 out of 100. The stock scores above average on value, quality and momentum – it is among the top 36% in our database. The score is made up of Value: 42/100, Quality: 79/100, Momentum: 72/100. In addition: a dividend of 3.04%; technical signal: Strong Buy. Whether Novartis is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Novartis stock?
The outlook for Novartis based on current data: the average analyst price target is $155.37 (+0.9%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 10/27/2026, which can move the price; the P/E ratio is 23.2 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Novartis stock moving?
Novartis is stable right now. The technical indicators show: the price is close to the 20-day average; insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Novartis go?
The average analyst price target for Novartis is $155.37, which corresponds to a potential gain of 0.9% from the current price of $153.93. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Novartis fall?
We lack enough history to give a specific floor for Novartis. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Novartis do?
Novartis, altså nvs.us, driver forskning, udvikling og salg af medicin over hele verden. De tjener primært penge på at levere farmaceutiske løsninger til komplekse sygdomme. Novartis er især kendt for lægemidler, der behandler hjerteproblemer, som Entresto, og autoimmune lidel... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - General industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Novartis as an investment.
Did Novartis raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Novartis. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Novartis making money or losing money?
Yes, Novartis is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 22.5% — which is excellent. The operating margin (profit before interest and taxes) is 34.6%. At a P/E ratio of 23.2, you currently pay 23.2 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Novartis go bankrupt?
The bankruptcy risk of Novartis is rated as moderate. Altman Z2 (a model for assessing financial distress) is 2.30 — that places the company in the middle zone. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 132% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Novartis have a lot of debt?
Novartis has moderate debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 132%. For the sundhed sector, 80-150% counts as a typical level. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Novartis service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 10.2x, and net debt equals 1.8 years of earnings (EBITDA).
